Evidence map›Paper›PMID 31015792›Full record

ArticleCurrent genomics2019

Profile of HBV Integration in the Plasma DNA of Hepatocellular Carcinoma Patients.

Weiyang Li, Xiaofang Cui, Qing Huo, Yanwei Qi, Yuhui Sun, Meihua Tan, Qingsheng Kong

Abstract read
In one paragraph

Article in Current genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Weiyang Li1Jining Medical University, Jining, Shandong272067, China; 2Collaborative Innovation Center for Birth Defect Research and Transformation of Shandong Province, Jining Medical University, Jining, Shandong272067, China; 3Southern University of Science and Technology, Shenzhen518055, China; 4Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen518002, China; 5Center for Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA19104, USA; 6BGI College, University of Chinese Academy of Sciences, Shenzhen518083, China.
Xiaofang Cui1Jining Medical University, Jining, Shandong272067, China; 2Collaborative Innovation Center for Birth Defect Research and Transformation of Shandong Province, Jining Medical University, Jining, Shandong272067, China; 3Southern University of Science and Technology, Shenzhen518055, China; 4Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen518002, China; 5Center for Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA19104, USA; 6BGI College, University of Chinese Academy of Sciences, Shenzhen518083, China.
Qing Huo1Jining Medical University, Jining, Shandong272067, China; 2Collaborative Innovation Center for Birth Defect Research and Transformation of Shandong Province, Jining Medical University, Jining, Shandong272067, China; 3Southern University of Science and Technology, Shenzhen518055, China; 4Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen518002, China; 5Center for Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA19104, USA; 6BGI College, University of Chinese Academy of Sciences, Shenzhen518083, China.
Yanwei Qi1Jining Medical University, Jining, Shandong272067, China; 2Collaborative Innovation Center for Birth Defect Research and Transformation of Shandong Province, Jining Medical University, Jining, Shandong272067, China; 3Southern University of Science and Technology, Shenzhen518055, China; 4Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen518002, China; 5Center for Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA19104, USA; 6BGI College, University of Chinese Academy of Sciences, Shenzhen518083, China.
Yuhui Sun1Jining Medical University, Jining, Shandong272067, China; 2Collaborative Innovation Center for Birth Defect Research and Transformation of Shandong Province, Jining Medical University, Jining, Shandong272067, China; 3Southern University of Science and Technology, Shenzhen518055, China; 4Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen518002, China; 5Center for Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA19104, USA; 6BGI College, University of Chinese Academy of Sciences, Shenzhen518083, China.
Meihua Tan1Jining Medical University, Jining, Shandong272067, China; 2Collaborative Innovation Center for Birth Defect Research and Transformation of Shandong Province, Jining Medical University, Jining, Shandong272067, China; 3Southern University of Science and Technology, Shenzhen518055, China; 4Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen518002, China; 5Center for Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA19104, USA; 6BGI College, University of Chinese Academy of Sciences, Shenzhen518083, China.
Qingsheng Kong1Jining Medical University, Jining, Shandong272067, China; 2Collaborative Innovation Center for Birth Defect Research and Transformation of Shandong Province, Jining Medical University, Jining, Shandong272067, China; 3Southern University of Science and Technology, Shenzhen518055, China; 4Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen518002, China; 5Center for Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA19104, USA; 6BGI College, University of Chinese Academy of Sciences, Shenzhen518083, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis B Viral (HBV) infection is one of the major causes of Hepatocellular Carcinoma (HCC). Mounting evidence had provided that the HBV integration might be a critical con-tributor of HCC carcinogenesis. OBJECTIVE AND

methodsTo explore the profile of HBV integration in the plasma DNA, the method of next-generation sequencing, HBV capture and bioinformatics had been employed to screen for HBV in-tegration sites in the plasma samples.

resultsIn the initial experiment, a total of 87 breakpoints were detected in the 20 plasma samples. The distribution of breakpoints showed that there was significant enrichment of breakpoints in the region of intron. Furthermore, the HBV breakpoints were prone to occur in the region of X protein (1,700-2,000bp) in the plasma samples. The pathway analysis had revealed that the HBV integrations sites were specifically enriched in the cancer pathway.

conclusionAltogether, our results had provided direct evidence for the HBV integration in plasma DNA, and they might be potentially useful for future HCC prognosis and diagnosis.

Indexed as

BreakpointsCell free DNAHBV genomeHBV integrationHepatocellular carcinomaPlasma

Identifiers

PMID31015792
PMCPMC6446477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.